Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125141) titled 'A randomized controlled clinical study of CICAPLAST BAUME B5+ in the treatment of EGFR inhibitor- related skin Adverse Reaction in cancer patients' on May 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Nanjing Medical University
Condition:
Cancer
Intervention:
Test group:Patients treated with CICAPLAST BAUME B5+
twice a day, apply to skin lesions such as head, neck, trunk, limbs, hands and feet (adjust according to the specific location of skin adverse reactions).Follow up 8 weeks +/-3 days
Control Group:Patients treated with Dimethicone Cream...